Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Onercept. Serono.

Spyros N Nikas1, Alexandros A Drosos

  • 1Department of Internal Medicine, Division of Rheumatology, Medical School, University of Ioannina, Ioannina 45110, Greece. snnikas@yahoo.com

Current Opinion in Investigational Drugs (London, England : 2000)
|February 5, 2004
PubMed
Summary

Onercept, a novel biologic, is being developed to treat inflammatory conditions like Crohn's disease and psoriasis. Clinical trials are progressing, with Phase III studies for psoriatic arthritis anticipated soon.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Extensive Subcutaneous Rheumatoid Nodules Reflecting High Burden of Disease Activity.

Mediterranean journal of rheumatology·2026
Same author

Regression and Disappearance of Accelerated Nodulosis with Adalimumab.

Mediterranean journal of rheumatology·2026
Same author

Beyond the Glands: Extraglandular Manifestations Associated With Sicca Symptoms in Systemic Sclerosis.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases·2026
Same author

Optimising Conventional Therapy in Rheumatoid Arthritis.

Mediterranean journal of rheumatology·2026
Same author

Subclinical atherosclerosis in patients with undifferentiated connective tissue disease: comparison with rheumatoid arthritis.

Clinical rheumatology·2026
Same author

Late onset axial spondyloarthritis presenting with fever of unknown origin. A case-based review.

Rheumatology international·2026

Area of Science:

  • Immunology
  • Pharmacology

Background:

  • Tumor necrosis factor (TNF) plays a key role in inflammatory diseases.
  • Onercept is a soluble TNF binding protein designed to neutralize TNF activity.

Purpose of the Study:

  • To evaluate Onercept as a potential therapeutic agent for inflammatory disorders.
  • To assess the safety and efficacy of Onercept in treating Crohn's disease, psoriasis, and psoriatic arthritis.

Main Methods:

  • Phase II clinical trials were conducted to assess Onercept's effects.
  • Ongoing trials monitor patient responses and disease progression.

Main Results:

  • Phase II trials were underway in March 2002 for Crohn's disease, psoriasis, and psoriatic arthritis.
  • Preliminary data from ongoing trials informed future development.

Conclusions:

  • Onercept shows promise as a treatment for TNF-mediated inflammatory conditions.
  • Further clinical development, including Phase III trials, is planned.

Related Experiment Videos